Persisting Platelet Activation and Hyperactivity in COVID-19 Survivors
Remy Martins-Gonçalves(Fundação Oswaldo Cruz), Patrı́cia T. Bozza(Fundação Oswaldo Cruz), Isaclaudia G. Azevedo-Quintanilha(Fundação Oswaldo Cruz), Rosana Souza Rodrigues(Universidade Federal do Rio de Janeiro), Lohanna Palhinha(Fundação Oswaldo Cruz), Paulo Henrique Rosado-de-Castro(Universidade Federal do Rio de Janeiro), Fernando A. Bozza(D’Or Institute for Research and Education), Mariana Macedo Campos(Fundação Oswaldo Cruz), Eugênio D. Hottz(Universidade Federal de Juiz de Fora), Júlia de Toledo-Mendes(Universidade Federal do Rio de Janeiro), Jairo R. Temerozo(Fundação Oswaldo Cruz), Mayara Abud Mendes(D’Or Institute for Research and Education)
Cited by 52
Related Papers
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
|Blood|2020|776
Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis
|Critical Care|2007|744
Lipid droplets: platforms with multiple functions in cancer hallmarks
|Cell Death and Disease|2020|530
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
|The Lancet Respiratory Medicine|2021|527